AI-generated · cited to primary sources · not investment advice · How we research
Tempus AI, Inc. - Class A Common Stock
Our verdict on Tempus AI, Inc. - Class A Common Stock isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company significantly exceeded the minimum liquidity requirement of $25 million, reporting $660.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025. (1 met across 1 tracked commitment)
“The Company is required to maintain a minimum liquidity of at least $25 million... The Company was in compliance with all covenants in the Credit Agreement as of September 30, 2025.”
R&D expenses increased from $119.7 million to $122.5 million for the nine months ended September 30, 2025, compared to the prior year period, confirming the absolute dollar growth trend. (1 met across 1 tracked commitment)
“These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.”
See the full cited Management analysis of Tempus AI, Inc. - Class A Common Stock
How durable is the business?
The company significantly expanded its proprietary technology moat through the acquisition of Ambry (hereditary cancer screening) and Deep 6 AI (clinical trial matching), adding substantial developed technology assets and customer relationships. (3 expanding)
“Each product line is designed to enable and enhance the other, thereby creating network effects in each of the markets in which we operate. We are able to commercialize records multiple times, both at the time a test is run and thereafter.”
The Data and services segment grew 36% year-over-year, largely due to a $16.5 million increase in demand for 'Insights' products, specifically the Pathos Foundation Model agreement. (4 expanding)
“Unlike traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data... we built both a technology platform to free healthcare data from silos and an operating system to make this data useful, the combination of which we refer to as our Platform.”
See the full cited Business Model analysis of Tempus AI, Inc. - Class A Common Stock
Where does growth come from?
The company is actively pursuing a new trend of inorganic growth through major acquisitions, specifically the pending $375 million acquisition of Ambry Genetics. (5 new trend across 5 signals, 1 leading indicator)
“The Paige Acquisition is expected to allow the Company to grow its dataset and establish a strong footprint in digital pathology with an industry leading technology portfolio.”
Genomics revenue (diagnostics) is accelerating significantly, nearly doubling year-over-year. This is driven by a 20% increase in oncology test volume and the massive addition of hereditary testing volume following the Ambry acquisition in February 2025. (4 accelerating, 1 steady across 5 signals, 1 leading indicator)
“The increase in Diagnostics revenue for the three months ended March 31, 2026, compared to the same period in 2025, was primarily due to an increase in the number of Oncology tests and the addition of Hereditary tests through the acquisition of Ambry in February 2025.”
See the full cited Future Growth analysis of Tempus AI, Inc. - Class A Common Stock
What could break the thesis?
The risk is easing slightly in terms of quarterly loss magnitude ($42.8M in Q2 2025 vs $552.2M in Q2 2024), though the accumulated deficit remains a long-term vulnerability. (1 easing, 2 stable, 1 intensifying, 1 high-severity)
“We have incurred significant losses and negative cash flows from operations since our inception, and as of March 31, 2026, we had an accumulated deficit of $2.5 billion.”
The risk is stable but remains high; while Medicare reimbursement rates increased, the company still relies heavily on securing reimbursement to achieve financial performance. (2 stable, 1 intensifying, 1 high-severity)
“As of December 31, 2025, we had received payment on approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests across all payers performed from January 1, 2023 through December 31, 2024.”
See the full cited Risk analysis of Tempus AI, Inc. - Class A Common Stock
Read the full thesis on Tempus AI, Inc. - Class A Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.